NO323359B1 - Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. - Google Patents

Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. Download PDF

Info

Publication number
NO323359B1
NO323359B1 NO19983456A NO983456A NO323359B1 NO 323359 B1 NO323359 B1 NO 323359B1 NO 19983456 A NO19983456 A NO 19983456A NO 983456 A NO983456 A NO 983456A NO 323359 B1 NO323359 B1 NO 323359B1
Authority
NO
Norway
Prior art keywords
bacteriophage
phage
bacterial
antibody
protein
Prior art date
Application number
NO19983456A
Other languages
English (en)
Norwegian (no)
Other versions
NO983456D0 (no
NO983456L (no
Inventor
Sven Mardh
Original Assignee
Phagen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phagen Ab filed Critical Phagen Ab
Publication of NO983456D0 publication Critical patent/NO983456D0/no
Publication of NO983456L publication Critical patent/NO983456L/no
Publication of NO323359B1 publication Critical patent/NO323359B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19983456A 1996-02-06 1998-07-27 Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. NO323359B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600434A SE506771C2 (sv) 1996-02-06 1996-02-06 Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
PCT/SE1997/000172 WO1997029185A1 (fr) 1996-02-06 1997-02-05 Phages de recombinaison

Publications (3)

Publication Number Publication Date
NO983456D0 NO983456D0 (no) 1998-07-27
NO983456L NO983456L (no) 1998-10-06
NO323359B1 true NO323359B1 (no) 2007-04-10

Family

ID=20401289

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19983456A NO323359B1 (no) 1996-02-06 1998-07-27 Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel.

Country Status (16)

Country Link
EP (1) EP0889955B1 (fr)
JP (1) JP4015195B2 (fr)
KR (1) KR100459638B1 (fr)
CN (1) CN1125174C (fr)
AT (1) ATE266091T1 (fr)
AU (1) AU712767B2 (fr)
CA (1) CA2244792A1 (fr)
DE (1) DE69728975T2 (fr)
ES (1) ES2221033T3 (fr)
HU (1) HUP9901242A3 (fr)
IL (2) IL125645A0 (fr)
NO (1) NO323359B1 (fr)
NZ (1) NZ331580A (fr)
RU (1) RU2215032C2 (fr)
SE (1) SE506771C2 (fr)
WO (1) WO1997029185A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522029A (ja) 1998-07-27 2002-07-23 ジェネンテック・インコーポレーテッド コートタンパク質の改変によるファージ提示における改良した形質転換効率
GB9908195D0 (en) * 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
WO2000077194A1 (fr) 1999-06-14 2000-12-21 Genentech, Inc. Structures peptidiques pour la mise en evidence de bibliotheques d'enroulements sur phage
ES2252263T3 (es) * 2000-07-25 2006-05-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Bacteriofago que tiene una gama de hospedadores multiple.
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
KR20040036176A (ko) * 2002-10-23 2004-04-30 (주)엘피스바이오텍 단백질의 특이적 결합을 매개로 한 박테리오파아지의선택적 숙주감염을 이용한 단백질간의 상호작용을분석하는 방법
CN102296051B (zh) * 2011-03-07 2014-09-17 江苏省农业科学院 一种宽宿主谱鸡白痢沙门氏菌噬菌体及其应用
RU2503716C1 (ru) * 2012-09-27 2014-01-10 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) ВИДОСПЕЦИФИЧЕСКИЙ ВИРУЛЕНТНЫЙ ШТАММ БАКТЕРИОФАГА, ОБЛАДАЮЩИЙ ЛИТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ Staphylococcus aureus, ВКЛЮЧАЯ МУЛЬТИРЕЗИСТЕНТНЫЕ ШТАММЫ
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
CN106198523A (zh) * 2016-07-06 2016-12-07 哈尔滨贝贝凯尔科技发展有限公司 微量元素检测试纸及其制备方法
EP3692370A2 (fr) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Articles et procédés destinés à la thérapie personnalisée du cancer
EP3909644A4 (fr) * 2018-12-27 2022-10-05 National University Corporation Tokai National Higher Education and Research System Nanoparticule spécifique à une bactérie hôte
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992018632A1 (fr) * 1991-04-12 1992-10-29 Stratagene Vecteurs polycos
SE9304060D0 (sv) * 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager

Also Published As

Publication number Publication date
SE506771C2 (sv) 1998-02-09
KR100459638B1 (ko) 2005-02-24
NZ331580A (en) 1999-09-29
RU2215032C2 (ru) 2003-10-27
ES2221033T3 (es) 2004-12-16
NO983456D0 (no) 1998-07-27
JP2000505648A (ja) 2000-05-16
IL125645A (en) 2006-08-20
NO983456L (no) 1998-10-06
EP0889955A1 (fr) 1999-01-13
CN1210558A (zh) 1999-03-10
SE9600434D0 (sv) 1996-02-06
HUP9901242A2 (hu) 1999-07-28
ATE266091T1 (de) 2004-05-15
CA2244792A1 (fr) 1997-08-14
DE69728975D1 (de) 2004-06-09
AU712767B2 (en) 1999-11-18
CN1125174C (zh) 2003-10-22
SE9600434L (sv) 1997-08-07
KR19990082041A (ko) 1999-11-15
JP4015195B2 (ja) 2007-11-28
IL125645A0 (en) 1999-04-11
HUP9901242A3 (en) 2000-03-28
AU1681797A (en) 1997-08-28
WO1997029185A1 (fr) 1997-08-14
DE69728975T2 (de) 2005-05-04
EP0889955B1 (fr) 2004-05-06

Similar Documents

Publication Publication Date Title
Cao et al. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth
Steiner et al. Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display
EP0889955B1 (fr) Phages de recombinaison
CN111848789A (zh) 抗sars-cov-2病毒s蛋白的单链抗体及其用途
CN102952191B (zh) 全人源抗cd33单链抗体zjl101及其应用
US20020044922A1 (en) Recombinant phages
Kwaśnikowski et al. Multivalent display system on filamentous bacteriophage pVII minor coat protein
AU661465B2 (en) Pseudomonas peptide composition and method for producing the same
Aikawa et al. Single-chain variable fragment (scFv) targeting streptolysin O controls group A Streptococcus infection
CN104710529B (zh) 一种抗鱼类病毒性出血性败血症病毒的单链抗体
US6497874B1 (en) Recombinant phages
JP2005508395A (ja) 炭疽菌毒素を検出および中和するための組換え抗体
Pokorny et al. Inhibition of Cryptosporidium parvum infection of a mammalian cell culture by recombinant scFv antibodies
Ojobor The Noncontractile Phage Tail-Like Bacterial Killing Nanomachines–Characterizing the Specificity Determinants of the F-Pyocins of Pseudomonas aeruginosa
CN114409778A (zh) 一种牛源抑制金黄色葡萄球菌溶血功能的单链抗体及其制备方法和用途
CN118344443B (zh) 一种增强噬菌体对肠黏膜黏附能力的蛋白a
CN105294840B (zh) 一种用于预防和治疗肠致病大肠杆菌感染的肽段
CN101198374B (zh) 具有抗hiv中和活性的抗体或其片段
CN112608383B (zh) 一种抗牙鲆弹状病毒的单链抗体
Kang The Characterization of a Novel Broad-spectrum Pseudomonas aeruginosa Receptor Binding Protein Derived From a Chimeric M13 Phage Display Library
CN114276447A (zh) 一种牛源抑制金黄色葡萄球菌生长的单链抗体及其制备方法和用途
JP2007236237A (ja) ベクターライブラリーの製造方法、人工ポリクローナル抗体の製造方法、及び医薬組成物の製造方法
Newsome et al. Human Single-Chain Fv Antibodies AgainstBurkholderia malleiandBurkholderia pseudomallei
Cappelletti et al. Structure-Function Analysis of the HrpB2-HrcU Interaction in the
Pootong Humanized antibodies that neutralize pertussis toxin activity